Search
Skip to Search Results- 10Vaccinia virus
- 6Immunotherapy
- 4Oncolytic virus
- 3Recombination
- 2Breast cancer
- 2Ribonucleotide reductase
- 1Chaurasiya, Shyambabu
- 1Crosley, Powel
- 1Gammon, Donald Brad
- 1Gupta, Nancy
- 1Molavi, Ommoleila
- 1Moussa, Eman W
-
Delivery of STAT3 inhibitor cucurbitacins to tumor by polymeric nano-carriers : Implications in cancer chemo- and immunotherapy
DownloadFall 2009
Signal Transducer and Activator of Transcription 3 (STAT3), a common oncogenic mediator, is constitutively activated in many types of human cancers and plays a critical role in tumor growth and cancer immune evasion. The focus of this dissertation is the delivery of STAT3 inhibitor cucurbitacins...
-
Vaccinia virus DNA polymerase and ribonucleotide reductase: their role in replication, recombination and drug resistance
DownloadSpring 2010
Despite the eradication of smallpox, poxviruses continue to cause human disease around the world. At the core of poxvirus replication is the efficient and accurate synthesis and repair of the viral genome. The viral DNA polymerase is critical for these processes. Acyclic nucleoside phosphonate...
-
Novel Agents Inhibiting Hepatitis C Virus; Application to Prevention of Re-infection after Liver Transplantation
DownloadFall 2013
Recurrent Hepatitis C virus infection drives inferior outcomes experienced by patients undergoing liver transplantation due to HCV-associated liver disease. Existing therapies exhibit increased toxicity, poor efficacy, and profound patient intolerability in the immediate transplantation period....
-
Fall 2014
Smallpox was eradicated using vaccinia viruses (VACV) as vaccines, including Dryvax, a calf-lymph vaccine derived from the New York City Board of Health (NYCBH) strain, and TianTan, a chicken egg cultured vaccine used exclusively in China. To take advantage of the next generation sequencing...
-
Spring 2016
Poxviruses, such as vaccinia virus (VACV) and myxoma virus (MYXV), actively modulate various cellular structures and functions to ensure effective replication and transmission. In the contrary, cells use several restriction mechanisms to mitigate these viruses. This evolutionary relationship is...
-
Fall 2016
Breast cancer (BrCa) is the most common cancer and the leading cause of cancer-related deaths in women worldwide. Current therapies for BrCa are insufficient to cure metastatic disease and are often associated with debilitating side effects that severely deteriorate the quality of patients’...
-
Spring 2017
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), continues to be a leading infectious cause of death worldwide with approximately 10 million new cases and 2 million deaths attributed annually. There has been resurgence in active TB infections since 1980s and the World Health...
-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Spring 2021
Vaccinia virus (VACV) has shown promise as an oncolytic agent for treating a variety of tumour types, with preliminary results suggesting that this strategy holds promise for treating breast cancer. Our lab has previously modified VACV by deleting virally-encoded enzymes responsible for dNTP...